IT / EN

Muscular Glycogen

Muscular Glycogen Storage Diseases are rare genetic disorders of glycogen metabolism, with an estimated prevalence of approximately 1:20,000 to 1:25,000.

The deficiency of a specific enzyme prevents the normal production of energy from muscle glycogen, leading to the abnormal accumulation of this molecule within muscle cells.

The primary symptoms include:

Exercise intolerance
Muscle cramps
Episodes of dark urine (myoglobinuria)
In more severe cases, progressive muscle weakness

The main types affecting the muscles are McArdle disease (Type V), Cori-Forbes disease (Type III), and Tarui disease (Type VII). The inheritance pattern for these conditions is autosomal recessive.

Each form corresponds to a deficiency of a specific enzyme within the glycogen metabolic pathway. The forms that primarily affect skeletal muscle include:

Type II (Pompe Disease): Deficiency of lysosomal acid alpha-glucosidase (GAA gene). It predominantly affects skeletal muscle and the heart.
Type III (Cori-Forbes Disease): Deficiency of the glycogen debranching enzyme (AGL gene). In the most common form (IIIa), both the muscle and the liver are involved.
Type V (McArdle Disease): Deficiency of muscle phosphorylase (PYGM gene). This is the most frequent form diagnosed in adults.
Type VII (Tarui Disease): Deficiency of muscle phosphofructokinase (PFKM gene).
Type IX: Deficiency of phosphorylase kinase (PHKA1, PHKB, and PHKG2 genes).

Clinical Presentation

The clinical picture varies depending on the specific enzyme deficiency and, to a lesser extent, the age of onset.

Type II (Pompe Disease): Due to the availability of specific treatment and the complexity of its clinical spectrum, this disease is managed separately. Please see the dedicated page on our website.
Type V (McArdle Disease): The dominant symptom is exercise intolerance with muscle cramps during physical activity and episodes of myoglobinuria (dark urine) after intense exertion. A hallmark feature is the “second wind” phenomenon: after a few minutes of activity, exercise tolerance improves significantly as the body switches to alternative energy substrates (such as free fatty acids and blood glucose). Serum creatine kinase (CK) levels—a biomarker of muscle damage—are persistently elevated even at rest, typically 5–50 times the normal range.
Type VII (Tarui Disease): The presentation is similar to McArdle disease regarding exercise intolerance and cramps, but the “second wind” phenomenon is absent. It is frequently associated with mild hemolytic anemia and hyperuricemia (elevated uric acid), caused by increased purine turnover.
Type III (Cori-Forbes Disease): In addition to exercise intolerance, patients experience progressive muscle weakness, which is initially distal and later proximal, with potential atrophy in advanced stages. Hepatic involvement typically manifests in childhood with hepatomegaly (enlarged liver) and fasting hypoglycemia, which tends to improve with age.

Laboratory Findings

CK (Creatine Kinase): Persistently elevated in almost all forms.
Hyperuricemia: A characteristic finding in Type VII.
Acute Episodes: During acute crises, elevated levels of serum and urinary myoglobin are found, carrying a significant risk of acute renal failure.

Clinical suspicion arises from the combination of exercise intolerance, recurrent cramps, episodes of myoglobinuria, and persistent hyperCKemia, especially when there is a compatible family history.

Lactate and Ammonia Exercise Testing: This test provides rapid diagnostic guidance. In muscular GSDs, lactate levels fail to rise after ischemic or submaximal exercise, while ammonia levels rise normally (an opposite pattern is observed in mitochondrial myopathies). The ischemic forearm exercise test, although less common today due to its invasiveness, provides similar information.
Muscle MRI: Identifies selective patterns of muscle involvement and assesses edema or fatty replacement, which are useful for characterizing disease activity and extent.
Muscle Biopsy: Reveals glycogen accumulation through PAS-positive vacuoles.
Enzymatic Activity Assay: Measuring enzyme activity in leukocytes, fibroblasts, or muscle tissue provides biochemical confirmation of the deficiency.
Molecular Diagnosis: Definitive diagnosis is achieved via targeted gene sequencing or NGS (Next-Generation Sequencing) panels for metabolic myopathies. Prenatal diagnosis is available for families with a known mutation.

Available therapies

Management and Treatment

For Glycogen Storage Diseases types III, V, and VII, there is currently no approved enzyme replacement therapy. Management relies primarily on dietary and behavioral interventions:

Nutritional Strategies

GSD Type III: A high-protein diet combined with uncooked cornstarch supplementation is recommended. This ensures a sustained release of glucose, maintaining stable blood sugar levels and reducing hypoglycemic episodes.
GSD Types V and VII: Ingesting rapidly absorbed carbohydrates (simple sugars) approximately 30 minutes before physical activity improves exercise tolerance by providing energy substrates that bypass the blocked muscle glycogen pathway.
General Recommendation: Prolonged fasting must be strictly avoided across all types.

Physical Activity and Rehabilitation

Aerobic Exercise: Low-intensity aerobic activity, preceded by an adequate warm-up, is recommended to maintain muscle function and metabolic efficiency.
Exercise Precautions: High-intensity or isometric exercise must be avoided to minimize the risk of rhabdomyolysis (muscle breakdown).
Physiotherapy: Essential for maintaining motor and respiratory functions, especially in progressive forms like GSD III.

Management of Acute Complications

Rhabdomyolysis: Acute episodes characterized by severe muscle pain and dark urine require intensive hydration (intravenous fluids) and close monitoring of renal function to prevent acute kidney injury.

Research in progress

Current research is focused on overcoming the metabolic blocks characteristic of GSDs through several innovative approaches:

Gene Therapy: Development of viral vectors (primarily AAV) designed to deliver functional copies of deficient enzymes directly to muscle tissue.
Metabolic Optimization: Strategies aimed at improving muscle energy metabolism, including the use of alternative substrates and pharmacological modulators of glucose pathways.
Biomarker Identification: Characterization of specific biomarkers of progression to better monitor the natural history of the disease and evaluate the efficacy of new treatments.
Dino Ferrari Center Involvement: The “Dino Ferrari Center” is actively involved in these research fields, participating in international networks and clinical trials to bridge the gap between laboratory discovery and patient care.